Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori

Phase

Condition

N/A

Treatment

Pantoprazole 40mg, Amoxicillin and Levofloxacin

Vonoprazan, Amoxicillin and Levofloxacin

Clinical Study ID

NCT06414707

FMASU R288/2023

Ages 18-70
All Genders

Study Summary

The goal of this Randomized controlled trial is to assessment Efficacy of Vonoprazan versus Proton Pump Inhibitors in Combination with Antibiotics as a triple Therapy for Eradication of Clarithromycin Resistant Strain of Helicobacter Pylori (H. pylori).

This randomized controlled study was performed on 2 groups of Egyptian patients diagnosed with dyspepsia; group (1) included 160 patients received Vonoprazan 20 mg oral once daily

Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days and group (2) included 160 patients received Pantoprazole 40 mg oral twice daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days. All patients of the two groups were followed up for persistence of infection 8 weeks after the end of treatment by testing fecal H. pylori antigen (Ag).

Eligibility Criteria

Inclusion

Inclusion Criteria:

patients with dyspepsia related to Clarithromycin-resistant strains of H.pylori. Allcases were diagnosed with H. Pylori resistant infection after clarithromycin basedtreatment regimen for H. pylori confirmed with persistent positive test of fecal H.pylori Ag before the starting of the study.
Must be able to swallow tablets.

Exclusion

Exclusion Criteria:

Cases with drug allergy from drugs included in the study.
those having inflammatory-bowel diseases.
those with malabsorption syndrome.
those having gastroenterology malignancy.
patients on immunotherapy.
HIV patients.

Study Design

Pantoprazole 40mg, Amoxicillin and Levofloxacin

October 12, 2023

April 04, 2024

Study Description

This randomized controlled trial included two groups of Egyptian patients diagnosed with dyspepsia related to Clarithromycin-resistant strains of H.pylori.

Group (1) included 160 patients received Vonoprazan 20 mg oral once daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for two weeks.
Group (2) included 160 patients received Pantoprazole 40 mg oral twice daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.

The included cases were collected from gastroenterology outpatient clinic and inpatient department at Ain shams University hospital between October 2023 and April 2024.

The work had been conducted after the scientific ethics committee approval and after obtaining an informed consent from all the included cases.

All cases were diagnosed with H. Pylori resistant infection after clarithromycin based treatment regimen for H. pylori confirmed with persistent positive test of fecal H. pylori Ag before the starting of the study.

All patients of the two groups were followed up for persistence of infection 8-weeks following the end of therapy by testing fecal H. pylori Ag. And the study end-points were compliance failure or gastrointestinal bleeding.

Each participant had been exposed to comprehensive taking of history, full physical assessment, full laboratory examination including (CBC, liver profile (ALT, AST), kidney functions test (S. creat), fecal H. pylori Ag testing before the starting of the trial and another stool sample were taken after termination of treatment by 8 weeks for evaluating of the eradication of H. pylori infection and pelvi-abdominal U/S was done for all patients.

Connect with a study center

Mostafa Elfors
Cairo, 3753450
Egypt
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.